CommercialCoverageHigh impact
Ixabepilone (Ixempra) (CPB 0869, reviewed 2026-04-07)
Aetna·Oncology, Hematology·Medical Policy
Effective date
Apr 7, 2026
We identified it
Aug 15, 2026
Summary
Aetna updated its coverage policy for Ixabepilone (Ixempra) effective April 7, 2026, establishing specific medical necessity criteria for breast cancer treatment. The policy covers ixabepilone as monotherapy for HER2-negative disease, as fourth-line combination therapy with trastuzumab for HER2-positive disease, and in combination with capecitabine for anthracycline/taxane-resistant disease with specific liver function requirements. All other indications, including triple-negative breast cancer and multiple other cancer types, are designated as experimental/investigational and not covered.
Action Required
By April 7, 2026: Billing team must update claim submission logic in billing software to require prior authorization for J9207 (ixabepilone) claims for Aetna commercial plans. Configure system to automatically deny claims for non-breast cancer indications (C16.0-C16.9, C18.0-C18.9, C25.0-C25.9, C34.00-C34.92, C40.00-C41.9, C53.0-C55, C56.1-C56.9, C61, C64.1-C65.9, C70.0, C71.6) as experimental/investigational. Create pre-authorization checklist requiring: (1) confirmation of HER2 status for metastatic/recurrent disease OR (2) documentation of prior anthracycline/taxane resistance plus AST/ALT ≤2.5 x ULN and bilirubin ≤1 x ULN for combination therapy, and (3) verification of baseline neutrophil count ≥1500 cells/mm3 and platelet count ≥100,000 cells/mm3. Providers must document that patients do not have severe (CTC grade 3/4) hypersensitivity to Cremophor EL. Update encounter templates to capture line of therapy (fourth line and beyond for HER2-positive combinations). Educate providers that ixabepilone for triple-negative breast cancer and all non-breast cancer indications will be denied. Implement ongoing monitoring requirement—claims for continuation beyond 12 weeks require documentation of stable disease (tumor size within 25% of baseline) or will be denied. Failure to obtain authorization or provide required documentation will result in claim denials.